ALPHAMAB ONCOLO.DL-000002 (3NK F) stock market data APIs

€0.7343 0(0%)
as of July 14, 2025
Try our APIs with free plan!

ALPHAMAB ONCOLO.DL-000002 Financial Data Overview

Price chart is built with Anychart

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is in Phase III clinical trials for treatment of HER2-positive breast cancer and HER2- positive gastric cancer or gastroesophageal junction cancer; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in Phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; JSKN016, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced malignant solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

Prev. Close 0.7343
Open 0.7343
High 0.7343
Low 0.7343
52 wk Range 0.212-1.01
Market Cap 775 M
P/E Ratio 40.25
Shares Outstanding 962 M
Revenue 640 M
Beta 0.498

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get ALPHAMAB ONCOLO.DL-000002 data using free add-ons & libraries


Get ALPHAMAB ONCOLO.DL-000002 Fundamental Data

ALPHAMAB ONCOLO.DL-000002 Fundamental data includes:

  • Net Revenue: 640 M
  • EBITDA: 165 M
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get ALPHAMAB ONCOLO.DL-000002 Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: NaN
  • EPS/Forecast: NaN
GET THE PACKAGE

Get ALPHAMAB ONCOLO.DL-000002 End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE
Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat